Please input keywords
Biocytogen to Present Pipeline Assets and R&D Progress at BIO International Convention, June 5-8, 2023

from clipboard

Biocytogen’s antibody BD and licensing (BDL) team will be delivering an oral presentation on Monday, June 5th at the 2023 BIO International Convention in Boston, taking place from June 5-8. The presentation will highlight Biocytogen’s clinical and preclinical pipeline assets, 6 fully human antibody discovery platforms, as well as the progress of Project Integrum, an initiative to develop therapeutic antibodies for more than 1000+ targets. Biocytogen’s BDL team will also host one-on-one partnering meetings at the event.


Using Biocytogen’s proprietary fully human antibody RenMiceTM, Biocytogen has built 6 antibody discovery platforms:

  • monoclonal antibody (mAb) platform: RenMabTM-based monoclonal antibody discovery with high affinity and great diversity;
  • bispecific antibody (BsAb) platform: RenLite®-based common light chain bispecific antibody discovery with high pairing success rate and good druggability;
  • bispecific ADC (BsADC) platform: high-throughput RenLite®-based bispecific ADC discovery for 200+ TAA targets with good tumor specificity, anti-tumor activity, and CMC efficiency;
  • nanobody platform: RenNano®-based single-domain antibody (nanobody) discovery with great blood-brain-barrier permeability and tumor infiltrating ability, suitable for the assembly of bispecific, multi-specific antibodies, CAR-T therapies, etc.
  • TCR-mimic antibody platform: HLA-transgenic RenMice-based TCR-mimic (TCRm) antibody divscovery for intracellular targets with superior affinity and specificity;
  • GPCR platform: target knockout RenMice-based antibody discovery for multi-species cross-recognition of GPCR and other challenging targets;

from clipboard

With an established in vivo efficacy screening platform and streamlined antibody development capability, Biocytogen launched Project Integrum to develop therapeutic antibodies for more than 1000+ targets. Since the initiation of Project Integrum, the company has generated 6 clinical stage assets:

  • YH003: CD40 mAb, which is currently in phase II MCRTs;
  • YH001: CTLA-4 mAb in an ongoing phase I clinical trial in partnership with TRACON for the treatment of sarcoma;
  • YH008: PD-1 × CD40 BsAb, which has received FDA and NMPA IND clearance, has been licensed in Greater China by Chipscreen NewWay Biosciences;
  • YH002: OX40 mAb, which is in phase I clinical trials in Australia and China;
  • YH004: 4-1BB mAb, which is in phase I clinical trials in Australia and China;
  • YH005: Claudin 18.2 mAb which has been out-licensed to RemeGen to develop Claudin 18.2 ADC, known as RC118.

and numerous preclinical stage assets:

  • 10+ fully human bispecific antibodies, including YH006 (CTLA-4 x OX40 BsAb);
  • 20+ bispecific antibody-drug conjugates, including YH012 (HER2 x TROP2 BsADC), YH013 (EGFR x MET BsADC) and BSA01 (EGFR x MUC1 BsADC);
  • 10+ TCR-mimic antibodies targeting intracellular TAAs, including WT-1, KRAS, P53, AFP, GP100 and NY-ESO-1;
  • 80+ monoclonal antibodies targeting B7H3, TNFR2, CCR8, AMHR2 and other novel TAAs, co-stimulatory/co-inhibitory molecules, tumor microenvironment molecules, GPCRs, and other popular targets;
  • 600+ antibody hits for oncology, inflammatory/autoimmune disease targets, infectious disease targets, and neurodegenerative disease targets, including B7H4, DLL3, MUC1, GPRC5D, PSMA, LRRC15, GUCY2C, LILRB2, NECTIN-4, ROR1, TIGIT and others.

Biocytogen’s antibody assets and RenMice platforms have been recognized by many pharmaceutical and biotech companies. As of December 31, 2022, Biocytogen has reached 34 preclinical antibody co-development or licensing agreements with 21 companies, including Merck KGaA, ADC Therapeutics, Hansoh Pharma, Chipscreen NewWay, LiberoThera, RemeGen, China Resources Biopharm and Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ). Additionally, the company has licensed RenMice (RenMab/RenLite) to 17 companies, including Merck KGaA, Janssen, BeiGene, Xencor and Innovent; 40 projects have initiated.

The team is looking forward to discussing licensing and co-development opportunities with you, either for antibody assets or fully human antibody discovery platforms. To schedule 1-on-1 partnering meetings, please visit For questions, or more information, please contact